Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Genitourinary 1Dermatologic 1

Conditions

Carcinoma, Non-Small-Cell Lung 7Colorectal Neoplasms 3Urinary Bladder Neoplasms 1Urethral Neoplasms 1Ureteral Neoplasms 1Stomach Neoplasms 1Small Cell Lung Carcinoma 1Pleural Effusion, Malignant 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Nasopharyngeal Neoplasms 1Mesothelioma 1Melanoma 1Lung Neoplasms 1Liver Neoplasms 1Kidney Neoplasms 1Fallopian Tube Neoplasms 1Esophageal Neoplasms 1Cholangiocarcinoma 1Carcinoma, Renal Cell 1Carcinoma, Ovarian Epithelial 1Carcinoma, Neuroendocrine 1Breast Neoplasms 1

Interventions

Trastuzumab 2Nivolumab 2trastuzumab deruxtecan 1tocilizumab 1tipifarnib 1pembrolizumab 1entinostat 1Thalidomide 1Ramucirumab 1Methods 1Lenalidomide 1Ipilimumab 1Interleukin-12 Subunit p35 1Interleukin-12 1Immunoglobulin G 1Gemcitabine 1Fentanyl 1Early Intervention, Educational 1Docetaxel 1Disulfides 1Carboplatin 1CTLA-4 Antigen 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Urethral Neoplasms × tocilizumab × Thoracic × Clear all
NCT04940299 2026-03-06

Tocilizumab, Ipilimumab, and Nivolumab for the Treatment of Advanced Melanoma, Non-Small Cell Lung Cancer, or Urothelial Carcinoma

M.D. Anderson Cancer Center

Phase 2 Active not recruiting
35 enrolled
DermatologicGenitourinaryThoracic

Urinary Bladder Neoplasms, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Melanoma, Ureteral Neoplasms, Urethral Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡